Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,414
archived clinical trials in
Overactive Bladder

Urinary Continence Index for Prediction of Urinary Incontinence in Older Women
Urinary Continence Index for Prediction of Urinary Incontinence in Older Women
Status: Enrolling
Updated:  1/5/2016
William Beaumont Hospital
mi
from
Royal Oak, MI
Urinary Continence Index for Prediction of Urinary Incontinence in Older Women
Urinary Continence Index for Prediction of Urinary Incontinence in Older Women
Status: Enrolling
Updated: 1/5/2016
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10002 Urology Centers of Alabama
mi
from
Homewood, AL
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10002 Urology Centers of Alabama
mi
from
Homewood, AL
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10004 Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10004 Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US00020 Urological Associates of Southern Arizona
mi
from
Tucson, AZ
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US00020 Urological Associates of Southern Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10003 Genesis Research
mi
from
San Diego, CA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10003 Genesis Research
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10010 Skyline Urology
mi
from
Sherman Oaks, CA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10010 Skyline Urology
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10028 Clinical Research Consulting
mi
from
Milford, CT
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10028 Clinical Research Consulting
mi
from
Milford, CT
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US00040 Coastal Connecticut Research
mi
from
New London, CT
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US00040 Coastal Connecticut Research
mi
from
New London, CT
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10033 Eastern Research
mi
from
Hialeah, FL
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10033 Eastern Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10023 Advanced Clinical Research of Miami
mi
from
Miami, FL
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10023 Advanced Clinical Research of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10007 Pinellas Urology, Inc
mi
from
Saint Petersburg, FL
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10007 Pinellas Urology, Inc
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10022 Palm Beach Research Center
mi
from
West Palm Beach, FL
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10022 Palm Beach Research Center
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10008 The Iowa Clinic PC, Urology
mi
from
West Des Moines, IA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10008 The Iowa Clinic PC, Urology
mi
from
West Des Moines, IA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10014 Mid Atlantic Clinical Research
mi
from
Greenbelt, MD
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10014 Mid Atlantic Clinical Research
mi
from
Greenbelt, MD
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10282 Boston Clinical Trials
mi
from
Boston, MA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10282 Boston Clinical Trials
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10026 AccuMed Research Associates
mi
from
Garden City, NY
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10026 AccuMed Research Associates
mi
from
Garden City, NY
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10013 Advanced Urology Centers of New York
mi
from
Plainview, NY
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10013 Advanced Urology Centers of New York
mi
from
Plainview, NY
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US00043 Upstate Clinical Research Associates, LLC
mi
from
Williamsville, NY
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US00043 Upstate Clinical Research Associates, LLC
mi
from
Williamsville, NY
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10017 The Jackson Clinic
mi
from
Jackson, TN
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10017 The Jackson Clinic
mi
from
Jackson, TN
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10057 Practice Research Organization
mi
from
Dallas, TX
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10057 Practice Research Organization
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10035 Millennium Clinical Research Center
mi
from
Arlington, VA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10035 Millennium Clinical Research Center
mi
from
Arlington, VA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10032 Clinical Research and Consulting Center, LLC
mi
from
Fairfax, VA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10032 Clinical Research and Consulting Center, LLC
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site US10034 Health Research of Hampton Roads Inc
mi
from
Newport News, VA
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site US10034 Health Research of Hampton Roads Inc
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated:  1/21/2016
Site CA15012 Glover Medical Clinic
mi
from
Langley,
A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Enrolling
Updated: 1/21/2016
Site CA15012 Glover Medical Clinic
mi
from
Langley,
Click here to add this to my saved trials
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Glendale, CA
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Newport Beach, CA
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Status: Enrolling
Updated:  2/8/2016
mi
from
Leuven,
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Status: Enrolling
Updated: 2/8/2016
mi
from
Leuven,
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
University of California Davis
mi
from
Davis, CA
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
Capital Region Urology
mi
from
Irvine, CA
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
Capital Region Urology
mi
from
Irvine, CA
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System
mi
from
Charlotte, NC
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System
mi
from
Charlotte, NC
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
Alliance Urology Specialists
mi
from
Greensboro, NC
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
Alliance Urology Specialists
mi
from
Greensboro, NC
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners
mi
from
Winston-Salem, NC
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated:  3/8/2016
Virginia Women's Center
mi
from
Richmond, VA
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status: Enrolling
Updated: 3/8/2016
Virginia Women's Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy
A Randomized Comparison of Concomitant Incontinence Procedures Performed With Abdominal Sacral Colpopexy: the Burch Versus Mid-urethral Sling Trial
Status: Enrolling
Updated:  3/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy
A Randomized Comparison of Concomitant Incontinence Procedures Performed With Abdominal Sacral Colpopexy: the Burch Versus Mid-urethral Sling Trial
Status: Enrolling
Updated: 3/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Conservative Treatment of Postprostatectomy Incontinence
Conservative Treatment of Postprostatectomy Incontinence
Status: Enrolling
Updated:  3/21/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Conservative Treatment of Postprostatectomy Incontinence
Conservative Treatment of Postprostatectomy Incontinence
Status: Enrolling
Updated: 3/21/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Feasibility Study Evaluating the ParaPatch System
A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder
Status: Enrolling
Updated:  3/28/2016
Skyline Urology
mi
from
Sherman Oaks, CA
Feasibility Study Evaluating the ParaPatch System
A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder
Status: Enrolling
Updated: 3/28/2016
Skyline Urology
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Feasibility Study Evaluating the ParaPatch System
A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder
Status: Enrolling
Updated:  3/28/2016
Skyline Urology
mi
from
Torrance, CA
Feasibility Study Evaluating the ParaPatch System
A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder
Status: Enrolling
Updated: 3/28/2016
Skyline Urology
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  5/11/2016
Clinical Research Facility
mi
from
Mountlake Terrace, WA
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 5/11/2016
Clinical Research Facility
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  5/11/2016
mi
from
Liege,
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 5/11/2016
mi
from
Liege,
Click here to add this to my saved trials
Vaginal Electrical Stimulation Versus Neuromodulation
Vaginal Electrical Stimulation Versus Sacral Neuromodulation for the Treatment of Refractory Overactive Bladder: A Pilot Study
Status: Enrolling
Updated:  6/8/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Vaginal Electrical Stimulation Versus Neuromodulation
Vaginal Electrical Stimulation Versus Sacral Neuromodulation for the Treatment of Refractory Overactive Bladder: A Pilot Study
Status: Enrolling
Updated: 6/8/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Robotic Assisted Laparoscopic Sacral Colpopexy Using Alyte Mesh
Status: Enrolling
Updated:  8/10/2016
Morristown Memorial Hospital
mi
from
Morristown, NJ
A Study of Robotic Assisted Laparoscopic Sacral Colpopexy Using Alyte Mesh
Status: Enrolling
Updated: 8/10/2016
Morristown Memorial Hospital
mi
from
Morristown, NJ
Click here to add this to my saved trials
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated:  8/15/2016
University of Missouri, Department of Internal Medicine
mi
from
Columbia, MO
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated: 8/15/2016
University of Missouri, Department of Internal Medicine
mi
from
Columbia, MO
Click here to add this to my saved trials
Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Status: Enrolling
Updated:  12/5/2016
Optimus Health care
mi
from
Stamford, CT
Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Status: Enrolling
Updated: 12/5/2016
Optimus Health care
mi
from
Stamford, CT
Click here to add this to my saved trials
Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Status: Enrolling
Updated:  12/5/2016
The Stamford Hospital
mi
from
Stamford, CT
Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Status: Enrolling
Updated: 12/5/2016
The Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
MRI (Magnetic Resonance Imaging) Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
Status: Enrolling
Updated:  12/12/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
MRI (Magnetic Resonance Imaging) Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon
Status: Enrolling
Updated: 12/12/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.
Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.
Status: Enrolling
Updated:  1/12/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.
Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.
Status: Enrolling
Updated: 1/12/2017
William Beaumont Hospital
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Huntsville, AL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Peoria, AZ
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Peoria, AZ
Click here to add this to my saved trials